Startup
STSiccaNova Therapeutics
Small-molecule drugs for exocrine gland dysfunction such as dry mouth.
Funding rounds
Grey amounts aren't counted in totals. † includes debt or other non-equity.
| Date | Company | Stage | Amount | Investors | Sector |
|---|---|---|---|---|---|
| 3 Sept 2026 | STSiccaNova Therapeutics | Series A | ¥1.25B | See source | BiotechDeep tech |